Using RSV to Target Prostate Cancer Cells
Author Information
Author(s): Echchgadda Ibtissam, Chang Te-Hung, Sabbah Ahmed, Bakri Imad, Ikeno Yuji, Hubbard Gene B, Chatterjee Bandana, Bose Santanu
Primary Institution: The University of Texas Health Science Center at San Antonio
Hypothesis
Can the respiratory syncytial virus (RSV) effectively target and kill androgen-sensitive prostate cancer cells?
Conclusion
RSV shows potential as a therapeutic tool for treating both androgen-sensitive and androgen-independent prostate cancer by inducing cell death.
Supporting Evidence
- RSV effectively induced apoptosis in LNCaP prostate cancer cells.
- RSV showed higher infectivity in cancer cells compared to non-tumorigenic cells.
- Impaired interferon response in LNCaP cells led to increased viral replication and oncolysis.
Takeaway
Researchers found that a virus called RSV can help kill prostate cancer cells without harming normal cells, making it a promising treatment option.
Methodology
The study involved in vitro and in vivo experiments to assess the oncolytic effects of RSV on prostate cancer cells.
Potential Biases
Potential bias due to the use of specific cell lines and animal models that may not reflect human responses.
Limitations
The study primarily focused on specific cancer cell lines and may not fully represent all prostate cancer types.
Participant Demographics
The study used human prostate cancer cell lines and murine models.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website